Price (delayed)
$3.27
Market cap
$354.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.21
Enterprise value
$332.54M
tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million
There are no recent dividends present for TNGX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.